anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The dynamic interplay between parenchymal hepatocytes and non-parenchymal cells (NPCs), such as macrophages, is an important mechanism for liver metabolic homeostasis. Although numerous endeavors have been made to identify the mediators of metabolic dysfunction associated steatohepatitis (MASH), the molecular underpinnings of MASH progression remain poorly understood, and therapies to arrest MASH progression remain elusive. Herein, it is revealed that the expression of grancalcin (GCA) is upregulated in the macrophages of patients and rodents with MASH and correlates with MASH progression. Notably, the administration of recombinant GCA aggravates the development of MASH, whereas, Gca deletion in myeloid cells blunts liver steatosis and inflammation in multiple MASH murine models. Mechanistically, GCA activates macrophages via TLR9-NF-κB signaling, and the activated macrophages promote hepatocyte lipid accumulation and apoptosis via secretion of Interleukin-6(IL-6), Tumor Necrosis Factor α (TNFα), and Interleukin-1β(IL-1β), thereby leading to hepatic steatosis and inflammation. Finally, the therapeutic administration of antibody blocking GCA effectively halts the progression of MASH. Collectively, these findings implicate GCA as a crucial mediator of MASH and clarify a new metabolic signaling axis between the hepatocytes and macrophages, implying that GCA can emerge as a particularly interesting putative therapeutic target for reversing MASH progression.
BACKGROUND AND PURPOSE: <p>Parkinson’s disease (PD) is a heterogeneous neurodegenerative disorder characterized by contradictory clinical outcomes among its several subtypes. The disease can manifest with a tremor-dominant (TD) or a non-tremor-dominant (NTD) phenotype. Although the TD subtype may show a better prognosis, there is limited information on the phenotypic differences regarding the level of axial symptoms. For this reason, in this study it was aimed to make a quantitative comparison of axial posture and spinal mobility between PD with TD and NTD. </p>.
METHODS: <p>This case-control study was conducted on 94 patients with diagnosed PD. A group diagnosis approach was used in the study, such that the diagnosis of each patient was confirmed, and they were assig-ned to TD and NTD groups by a neurologist expert on movement disorders. Of the patients with PD, 61 were in the TD group, and 33 were in the NTD group. Spinal mouse was used to measure spinal posture and spinal mobility in both sagittal and frontal planes. </p>.
RESULTS: <p>Two groups of 61 patients (25 male + 36 female) with TD-PD (mean age: 64.49±10.37 years) and 33 patients (20 male +13 female) with NTD-PD (mean age: 63.45±9.11 years) were enrolled in the study. There were no significant differences bet­ween the patients with TD and NTD in terms of sagittal and frontal postures (p>0.05). In addition to this, anterior trunk tilt was found to significantly increase as the disease stage advanced in both groups. While the greatest anterior trunk tilt change in the TD-PD group was observed in the 3rd stage, NTD-PD group was in the 2.5th stage. Aside from this, the out­comes of the spinal mobility measurements in the frontal and sagittal planes were similar between the groups (p>0.05).</p>.
CONCLUSION: <p>It is widely acknowledged that many clinical aspects of the TD and NTD forms of PD differ; however, in our study, it was observed that there may be no difference in the axial symptoms of the patients with PD in terms of classification according to tremor dominance.</p>.
The invention relates to an anti-dandruff shampoo comprising: a) from 0.1 to 5 wt. % of an anti-dandruff zinc salt; b) from 2 to 16 wt. % of an alkyl sulphate and/or an ethoxylated alkyl sulfate anionic surfactant; and, c) from 1 to 10 wt. % of a fatty acyl isethionate product which product comprises 40 to 80 wt. % fatty acyl isethionate and 15 to 50 wt. % free fatty acid and/or fatty acid salt and to the use of the fatty acyl isethionate product to provide a conditioning benefit to hair treated with an anti-dandruff shampoo comprising anti - dandruff zinc salts.
All infants and children born to women who received atosiban (in 3 successive stages; an initial bolus dose of 6.75 mg using atosiban 6.75 mg per 0.9 milliliter \[mL\] solution for injection, followed by continuous high dose infusion at 18 mg per hour for 3 hours, then a lower 6 mg per hour infusion for the remainder of the 48-hour using the atosiban 37.5 mg per 5 mL concentrate for solution) in 200721 study. Current study will not require any medical interventions or study visits to an investigational site.
The surgical procedure in group A consisted of the placement of a 6.4cm diameter circular prosthesis (BARD Hernia Patch) at the intra-abdominal level. Subsequently, the liquid contained in the 10 ml opaque vial was administered (Ecolav Physiological Washing Serum 0.9%, (SSF).
PROBLEM TO BE SOLVED: To obtain the subject dental material containing metallic powder, high in fracture toughness, excellent in wear resistance and long-term durability, and useful for molar site filling restoration in dental therapies. SOLUTION: This restorative dental material comprises a total 100 pts.wt. of (A) 60-98 pts.wt. of metallic powder (pref. silver powder or silver-contg. alloy powder, normally 1-1000μm in average particle size) (B) 2-50 pts.wt. of a polymerizable monomer, (C) 0.01-30 pts.wt. of a polymerizable monomer having affinity for the metal, and (D) 0.01-20 pts.wt. of a polymerization initiator. It is preferable that the metallic powder is treated, in advance, with the component C to effect adherence thereof to the surface of the metallic powder.
The invention discloses a traditional Chinese medicinal composition for treating rhinitis. The composition consists of the following raw materials by weight: 15-25 parts of Bothriospermum chinense Bunge, 15-25 parts of magnolia flower, 15-25 parts of mint, 15-25 parts of Angelica dahurica Benth. et Hook, 15-25 parts of radix sileris and 15-25 parts of Ligusticum wallichii. A preparation method is as below: taking 90 grams of Bothriospermum chinense Bunge, magnolia flower, mint, Angelica dahurica Benth. et Hook, radix sileris and Ligusticum wallichii by weight parts, adding water, decocting for 30 min, pouring out a soup, then adding water again, decocting for 30 min, pouring out a soup, mixing the two soups, and taking by two times in the morning and evening after meal. The composition employs six medicinal herbs, uses easily available raw materials with rich source, is simple for production and low in cost; the composition has mild medical property, little side effects, is easy to take, and has good effect in the treatment of rhinitis.
Compounds of the formula: (I) [wherein A is the formula: (III-1) R is a hydrogen atom, lower alkyl, etc.; m is 0 or 1; R is a hydrogen atom, halogen atom, etc.; R is a hydroxyl, etc.; p is 0 to 4; X is a carbon atom or nitrogen atom; and each of X to X is a lower alkyl, etc.], or pharmaceutically acceptable salts thereof. These have a potency antagonistic to binding to histamine H3 receptor, or have a potency inhibiting the constant activity of histamine H3 receptor, and are useful in the therapy of obesity, diabetes, etc.
Recent advances in antibody cloning technologies have led to the discovery of a number of highly potent, HIV-specific, broadly neutralizing monoclonal antibodies from B cells of HIV-infected individuals. It has been shown that certain broadly neutralizing HIV-specific antibodies can prevent acquisition of the virus, suppress viral replication, delay and/or prevent plasma viral rebound following treatment interruption in Simian Immunodeficiency virus (SIV)-infected animals and block cell-to-cell transmission of laboratory-adapted HIV in vitro. However, it is unclear what in vivo effects these antibodies might have on plasma viral rebound in HIV-infected individuals following discontinuation of combination antiretroviral therapy (cART).

In this regard, it has been shown that virtually all infected individuals who initiated cART during the chronic phase of infection experience plasma viral rebound upon cessation of therapy. Current research on the treatment of HIV-infected individuals has been heavily focused on developing strategies aimed at achieving sustained virologic remission in the absence of cART. Thus, it is of great interest to investigate whether a potent HIV-specific monoclonal antibody, such as VRC01, can prevent plasma viral rebound in infected individuals upon discontinuation of cART. We propose to examine the effect of VRC01 on plasma viral rebound in HIV-infected individuals following analytical treatment interruption (ATI).
OBJECTIVES: Data driven strategies for acute pancreatitis (AP) in pediatrics are limited; adult data suggests lactated ringers (LR) compared to normal saline (NS) resulted in favorable outcomes, but has not been studied in pediatrics. Our objective was to evaluate the efficacy of LR during the first 48 h of an AP episode compared with NS.
STUDY DESIGN: A multisite randomized controlled clinical trial, from 2015 to 2020 (Clinical Trials.gov NCT03242473). Patients were randomized to exclusively LR or NS for the first 48 h. Primary outcomes were serial C-reactive protein (CRP) values. Secondary outcomes included other lab values, time to feeds, length of stay (LOS), systemic inflammatory response syndrome (SIRS) development, and progression to severe AP (SAP).
RESULTS: We studied 76 patients (38 LR, 38 NS). CRP at 24 and 48 h were not significantly different between LR or NS group. Additionally, there were no differences in trends of BUN, amylase, lipase, SIRS status, or SAP development between the LR and NS group at 24 and 48 h. A higher proportion of LR patients (32%, 12/38) were discharged before 48 h compared to NS (13%, 5/38). The LR group had a significantly higher rate of discharge within the first 72 h compared to the NS group (p = 0.02).
CONCLUSION: The use of LR was associated with a faster rate of discharge during the intervention period and in the first 72 h, but no other differences compared to NS. This reduction in length of hospitalization has significant implications for patients and healthcare costs.
Subject included in the placebo group will receive placebo. The dose consists on 2 spray puff every 12 hours for 45 days.
With the increase in the number of people with advanced age (> 60 years) worldwide, it is necessary to understand the processes that lead to healthy aging. Cellular senescence, immunosenescence and inflammaging are part of the natural process of aging and are associated with age-related diseases. Cellular senescence is characterized by the arrest of the cell cycle in the G1 phase. Senescent cells can be identified by different markers (surface or intracellular), by changes in their functions, and by their gene expression profile. Immunosenescence causes dysregulation of the immune response, with persistent (chronic) increases in inflammatory mediators and decreases in the effectiveness of immune effector responses, which promotes the development and severity of chronic-degenerative diseases and fragility. When immunosenescence is related with advanced age, it is known as inflammaging. New strategies to revert immunosenescence are currently being investigated, with senotherapy with senolytic drugs that eliminate senescent cells, and with senomorphic drugs that inhibit the secretion of senescence-promoting mediators. Senolytic drugs may be useful during the aging process, to delay, prevent and/or improve age-related diseases.
Patients receive 4 mg ixazomib by mouth on days 1, 8 and 15. Patients also receive 15 mg lenalidomide by mouth on days 1-21, 12 mg dexamethasone by mouth on days 1, 8, 15, and 22 and zoledronic acid (dose based on creatinine clearance on day 1) IV infusion on day 1. Patients receive treatment every 28 days for a maximum of 6 cycles.
PURPOSE: An inhibitor to SCV(severe acute respiratory syndrome) corona virus containing a specific oligonucleotide is provided to suppress double helix DNA unwinding activity of helicase of SCV corona virus. CONSTITUTION: An oligonucleotide contains MAAGGRGAMV sequence of sequence number 1. In the sequence, M is adenine or cytocine, R is purine, V is adenine, guanine or cytocine. The oligonucleotide has AAAGGRGAAG of sequence number 2. The oligonucleotide is an oligonucleotide of sequence number 3 which further comprises G at seventh base site. The oligonucleotide further comprises GAAAG sequence 3'-terminal downstream.
Participants in this arm will receive information only. Participants will be followed up at 4 months and 6 months.
An anti-infective coating for a sharp-edged metal instrument. The coating is insoluble in a biological medium and is bound to the metal instrument such as needles and scalpel blades. The coating is a biocompatible, non-hydrogel polymer. One embodiment is a coating on the metal which is complexed with an iodine solution to provide a programmed rapid release of iodine. A second embodiment is a solution of the biocompatible hydrogel polymer in which the iodine is dissolved and the solution containing iodine is coated in the sharp-edged metal instrument to provide a matrix having programmed sustained release of iodine. A coating with complexed iodine may be deposited over a coating with matrixed iodine to provide an anti-infective coating on a sharp-edged metal instrument with a rapid release and a sustained release of iodine over a period of weeks. A non-iodized polymer coating may be deposited on the complexed coating, the matrixed coating or the combined coating to provide protection to the sub coating and to further control the rate of release of iodine. The iodine containing coating provides a concentration of iodine that has sufficient activity and is available for a period of time which is long enough to allow germs to be inactivated. The coated device is stable and has long shelf life. The coated device effectively inactivates human immunodeficiency virus.
Pulmonary vein isolation (PVI) is a well-established interventional treatment of patients with atrial fibrillation. Previous studies have shown that catheter-based treatments such as PVI may lead to cerebral ischemia. Cerebral ischemia related to PVI may present with new neurological deficits but may also occur as "silent brain infarction". However, even "silent brain infarctions" are associated with an increased risk of incident dementia and clinically overt new strokes. To date, it remains unclear which procedural steps of PVI are associated with an increased risk of cerebral ischemia.

Cerebral blood flow and microembolic signals can be detected by using transcranial doppler ultrasound (TCD). TCD has been used in clinical routine for many years and is known to be safe in stroke patients. By performing continuous TCD monitoring for microembolic signals during PVI, the aim of this study is therefore to identify, which procedural steps are associated with the occurence of cerebral microemboli. In addition, the investigators aim to compare the frequency of cerebral microemboli in different pulmonary vein isolation techniques, namely high-power with a maximum of up to 50 W (QMODE) and very high power with a maximum of up tp 90 W (QMODE +)
A beautiful face pad for improving facial wrinkle is provided to provide moisturizing effect to the skin by attaching a pack in which a collagen, vitamin and aloe are added at crowfeet, forehead, a middle between eyes, and wrinkle around lips, to maintain an elasticity of the skin by supplying nutrition to the skin and to suppress, relax and prevent the skin aging. A beautiful face pad includes a silicon sheet including a coating layer on which a wrinkle removing agent is coated and a base sheet manufactured using an aromatic polypropylene preserving an original form of the silicon sheet. The wrinkle removing agent is manufacture by mixing aloe of 20~40 weight%, collagen of 20~40 weight%, vitamin of 30~50 weight%. An air flowing hole for circulating air is formed at the base sheet. The beautiful face pad(10) putting on the wrinkle of the forehead has a shape of ellipse. Beautiful face pads(11,13) used in crows feet and the lip wrinkle have a crescent shape. A beautiful face pad(12) for wrinkle of the middle of the forehead has a shape of a diamond.
The invention discloses a traditional Chinese medicine composition for treating Behcet's disease and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from, by weight, 32-39 parts of Schnabelia oligophylla Hand-Mazz., 10-18 parts of Solanum surattense Burm., 25-35 parts of Stachys kouyangensis (Van.)Dunn and 3-8 parts of small-fruited balloon vine fruits. The method comprises the steps that a microwave extract is prepared from the Schnabelia oligophylla Hand-Mazz., the Stachys kouyangensis (Van.)Dunn and the Solanum surattense Burm. By smashing, extracting in a microwave mode,, adsorbing, eluting and concentrating; the small-fruited balloon vine fruits are cleaned and then dried, smashed and screened through a 200-mesh screen to obtain ground small-fruited balloon vine fruits; the microwave extract and the ground small-fruited balloon vine fruits are mixed and dried with stirring at the temperature of 50-55 DEG C to obtain the traditional Chinese medicine composition. Under the joint action of all the components, the traditional Chinese medicine has the excellent effect on the Behcet's disease, pain is relieved, the service life is prolonged, medication safety is achieved, the curative effect is stable, the disease does not reoccur after being cured, no toxic or side effect exists, and the traditional Chinese medicine is simple in preparation process, easy to produce and manufacture, convenient to carry and low in cost.
FIELD: medicine. SUBSTANCE: method involves carrying out tooth cleaning in prescribed sequence daily using one of three tooth brushes. Electrophoretic tooth brush having positive emitting electrode, one having negative emitting electrode, ordinary tooth brush are useable with a corresponding tooth paste or gel. The pastes and gels have biologically active ingredients forming mineralization element ions in aqueous medium having, as a rule, electric charge of the same sign. Non-ionogenic or cation-active surface active substances in one case are present as detergent agents. Non-ionogenic or anion-active surface active substances in the other case are used as detergent agents. EFFECT: enhanced curative and prophylaxis effectiveness in treating caries. 8 cl, 5 tbl
Oral isotretinoin was administered using the same method as the isotretinoin group, while microneedle radiofrequency therapy was also administered.Using the Peninsula radiofrequency therapy device (Peninsula Company, China). A total of 3 treatments were conducted, with a treatment interval of 1 month, and the total course of treatment was 8 weeks.
Up to 154 patients will be recruited in the TACTI-003 (Two ACTive Immunotherapies) Phase IIb study which will take place across several countries in Australia, Europe and United States of America in up to 35 experienced clinical sites. It will evaluate the safety and efficacy of eftilagimod alpha in combination with pembrolizumab against pembrolizumab alone in 1st line metastatic or recurrent HNSCC with PD-L1 positive (CPS ≥1) tumors, and determine the efficacy and safety of efti plus pembrolizumab in patients with PD-L1 negative tumors. Subjects in cohort A (CPS ≥1) will be randomized 1:1 to receive either "P+E": efti plus pembrolizumab or "P only": pembrolizumab alone. Subjects in cohort B (CPS \<1) will receive a combination of efti and pembrolizumab "P+E". Efti will be administered for up to 24 months using a 30 mg s.c. dosing every 2 or 3 weeks. Pembrolizumab will be administered for up to 24 months using a 400mg i.v. (30 min) dosing every 6 weeks.
Despite limited research on refractory and/or endocrine therapy failure in elderly metastatic breast cancer (MBC) patients, a prior study showed that low-dose oral cyclophosphamide (CY) can improve the overall survival rate of MBC patients, possibly through the immunoregulation of regulatory T cells (Tregs). We preliminarily investigated the combination of endocrine therapy (ET) with oral low-dose CY as salvage therapy in elderly patients via peripheral blood regulatory T-cell analyses. In addition, we evaluated the associations of tumor tertiary lymphoid structures (TLSs) with therapeutic outcomes. HR+/HER2- advanced breast cancer patients who received low-dose CY combined with ET or ET only from April 2015 to August 2021 were enrolled in this retrospective study. The primary outcome was the clinical control rate (CCR), and the secondary outcome was progression-free survival (PFS). Circulating T lymphocyte subpopulations represented by Tregs were monitored during treatment by flow cytometry methods. TLSs wereconfirmed by hematoxylin-eosin staining of pretreatment specimens, and CD3, CD4, and Foxp3 were detected using Opal multicolor immunofluorescence. A total of 85 patients who received CY + ET and 50 patients who received ET only were enrolled, the percentage of patients who received CCR was 73% (62/85) vs. 70% (45/50), and the objective response rate (ORR) was 28% (24/85) vs. 24% (12/50). No deaths occurred during the study period. The mean PFS time was 13 vs. 11 months (P = 0.03). In the CY + ET group, decreases in CD4+/CD25+/Foxp3+ T cells (P < 0.001) were favorable for both clinical control and prolonged PFS (P < 0.001). Compared with patients without TLSs, those with TLSs were more likely to have better clinical control and PFS (mean time = 6 months), and a greater number of Treg cells during TLS pretreatment correlated with longer PFS (P = 0.043). Oral low-dose CY combined with standard ET exerts immunological effects by decreasing Treg levels to achieve improved clinical responses. Moreover, patients with TLSs might benefit more from such therapy than those without TLSs, and a high Treg cell count in TLSs before treatment predicts better therapeutic efficacy.
Conventional 1-form crystals of 5-hydroxy-1-methylhydantoin contain, remaining therein in a considerable amount, the organic solvent used in a purification step. In contrast, in II-form crystals, the amount of the organic solvent remaining therein is smaller than the detection limit. Namely, the II-form crystals contain substantially no residual organic solvent. The novel II-form crystals of 5-hydroxy-1-methylhydantoin obtained through recrystallization from water not only contain substantially no residual organic solvent, but also have a high bulk density and are hence advantageous for pharmaceutical preparation. They further have properties advantageous for production, such as low adhesion. The crystals are significantly useful as a material for medicines required to have high safety, such as drugs for renal insufficiency.
SOTYLIZE is an aqueous solution containing sotalol hydrochloride.

Sotalol hydrochloride is a white, crystalline solid with a molecular weight of 308.8. It is hydrophilic, soluble in water, propylene glycol and ethanol, but is only slightly soluble in chloroform. Chemically, sotalol hydrochloride is d,l-N-[4-[1-hydroxy-2-[(1-methylethyl) amino]ethyl]phenyl]methane-sulfonamide monohydrochloride. The molecular formula is C12H20N2O3S HCl and is represented by the following structural formula:

SOTYLIZE is a grape-flavored aqueous solution. Each mL contains 5 mg sotalol HCl. Inactive ingredients are sodium citrate, citric acid, sucralose, sodium benzoate and purified water.